Drug intelligence / Profile preview

zabofloxacin

Development stage: Phase 3
Lead developer: Dongwha Pharmaceutical
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Zabofloxacin is a fluoroquinolone antibiotic developed for the treatment of bacterial infections, particularly those caused by Gram-positive bacteria such as *Streptococcus pneumoniae* and methicillin-resistant *Staphylococcus aureus* (MRSA). It acts by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication and cell division. Zabofloxacin was originally developed by Dong Wha Pharmaceutical in South Korea. Its primary indication is for respiratory tract infections, including community-acquired pneumonia.

Brand names: Zabocin
Other names: zabofloxacin hydrochloride

Targets

DNA gyraseTopo IV (Bacterial Topoisomerase IV)

Beyond the preview

Go deeper on zabofloxacin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on zabofloxacin.

Explore the full profile